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Abstract
Generation of reactive oxygen species and mitochondrial dysfunction has been implicated in doxorubicin-induced cardiotoxicity. This
study examined pro-apoptotic mitochondrial cell death signals in an H9C2 myocyte rat cell line and in isolated rat heart mitochondria
exposed to doxorubicin. Mitochondrial and cellular viability were assessed using an MTT viability assay (formazan product formed by
functional mitochondrial dehydrogenases) and calcein AM dye (fluoresces upon cleavage by cytosolic esterases). Mitochondrial dysfunction
followed by cell death was observed using nM concentrations of doxorubicin. Significant doxorubicin-induced cell death was not apparent
until after 6 h following doxorubicin exposure using the calcein AM assay. The involvement of apoptosis is evidenced by an increase in
TUNEL (terminal (TdT)-mediated dUTP-biotin nick end labeling)-positive nuclei following doxorubicin treatment. Furthermore,
doxorubicin administered to isolated mitochondria induced a rapid increase in superoxide production, which persisted for at least 1 h and
was followed by increased cytochrome c efflux. In addition, caspase-3 activity was increased with doxorubicin administration in the H9C2
myocyte cell line. An oxidant-mediated threshold of mitochondrial death may be required for doxorubicin-induced apoptosis.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Doxorubicin is a powerful anthracycline antibiotic used
to treat a multitude of human neoplasms; however, cardiac
toxicity compromises the clinical usefulness of the drug
[1,2]. It is believed that mitochondria play a significant role
in this toxicity as isolated heart mitochondria and myocytes
have been shown to give rise to increased levels of oxygen
radicals after doxorubicin treatment [3–8]. The chronic side
effects of doxorubicin are irreversible and devastating for
the patient and include the development of cardiomyopathy
and ultimately congestive heart failure [1,2]. Although
recent evidence shows that less toxic doses of doxorubicin
can be used effectively, heart failure in doxorubicin treated
patients can go undetected for many years [9]. Therefore, it
is essential to identify the mechanisms by which doxorubi-
cin is cardiotoxic so that interventions to prevent the
cardiotoxic effects of doxorubicin can be developed.
Doxorubicin-induced cardiomyopathy is partially caused
by increased oxidant production in the heart [6,10–14]. The
mitochondria are believed to be a primary sink for doxor-
ubicin and specific dehydrogenase systems produce super-
oxide anions [7]. Single electrons are shuttled to
doxorubicin, giving rise to oxygen radicals through the
auto-oxidation of doxorubicin and semiquinones [7,15].
Moreover, Kotamraju et al. [6] recently showed that hydro-
gen peroxide produced from the superoxide anion might be
the key oxidant responsible for doxorubicin-induced apop-
tosis in endothelial cells and cardiomyocytes.
Mitochondria play a pivotal role in regulating apoptosis
by mechanisms such as release of cytochrome c that results
in the activation of caspases and subsequent cell death
[16,17]. The mitochondria respond to several signals (i.e.
reactive oxygen species, altered redox status, and increases
in calcium levels), which trigger the release of caspase-
activating proteins, such as cytochrome c and apoptosis-
inducing factor [18]. The release of cytochrome c from the
mitochondria into the cytosol can result in the activation of
caspase-9, which is responsible for activating effector cas-
pases, such as caspase-3, to induce cell death.
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This study examined doxorubicin-induced mitochondrial
dysfunction and pro-apoptotic markers in a rat cardiac
myocyte cell line and in isolated mitochondria from rat
heart. In this study, we show that mitochondrial dysfunction
may be an important early step in the regulation of doxor-
ubicin-induced release of cytochrome c from the mitochon-
dria. Our results show that when H9C2 cells are exposed to
very low (nM) concentrations of doxorubicin, a rapid
decline in mitochondrial reduction potential precedes cell
death by approximately 6 h, implicating mitochondrial
dysfunction as an early event in doxorubicin-induced car-
diotoxicity. In addition, we show that doxorubicin treatment
to isolated mitochondria causes a rapid increase in radical
production, which can be maintained for over 1 h. Under-
standing the time-course of doxorubicin toxicity and the
underlying causes of doxorubicin-induced cardiomyopathy




H9C2 cells (ATCC, Rockville, MD) were maintained in
DMEM supplemented with 10% FBS in 95% air:5% CO2
using standard culture methods. Cells were plated 24 h prior
to doxorubicin treatment at a density of 150 cells/mm2.
All studies were conducted in the presence of 10% FBS.
Although growth factors and other possible confounding
factors are present in the serum, removing the serum from
the experiments could also confound interpretation through
altering the baseline viability of the cultures and causing
apoptotic changes independently of the doxorubicin treat-
ment.
2.2. Viability assay
Cells were rinsed once with PBS followed by incubation
at (37 jC) with 25 AM calcein AM and 1 mg/ml propidium
iodide for 15 min. Fluorescence was measured at ex 485/em
530 and ex 480/em 620, respectively. 3-(4,5-Dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction
was determined by incubating cells with 0.25 mg/ml MTT
in the culture media at 37 jC for 3 h. Formazan crystals
were solubilized by overnight incubation in 50% N,N-
dimethyl formamide, 20% sodium dodecyl sulfate, pH 4.8
and absorbance determined at 575 nm.
2.3. Mitochondrial isolation
Mitochondria were immediately isolated from the ven-
tricles of a rat heart as previously described [19]. Briefly,
tissue was weighed and minced in 10 volumes of isolation
buffer (0.225 M mannitol, 0.075 M sucrose, 0.2% fatty acid
free bovine serum albumin, pH 7.4). The tissue was homo-
genized in a Potter-Elvehjem glass homogenizer and cen-
trifuged for 7 min at 480g. The resulting supernatant was
stored on ice while the pellet was resuspended in 5 ml of
isolation buffer and centrifuged for 7 min at 480g. The
combined supernatants were centrifuged for 7 min at
7700g. The supernatant was decanted and the mitochon-
drial pellet was resuspended in 5 ml of wash buffer (0.225
M mannitol, 0.075 M sucrose, 0.001 M EGTA, pH 7.4)
using a cotton swab so as not to break the mitochondria and
then centrifuged for 7 min at 7700g. The final mitochon-
drial pellet was resuspended in 1 ml of storage buffer (0.25
M sucrose, 0.002 M EDTA pH 7.4) and immediately used
for experiments.
2.4. Superoxide anion measurement
Superoxide anion generation in isolated rat heart mito-
chondria was determined immediately following the isola-
tion procedure. Briefly, mitochondria (0.5 mg/ml) were
incubated with buffer (6 mM succinate, 70 mM sucrose,
220 mM mannitol, 2 mM, Hepes, 25 mM KH2PO4, 2.5 mM
MgCl2, 0.5 mM EDTA, 5 Ag/ml catalase, pH 7.4) and 10
AM doxorubicin at 37 jC. At the indicated time points, 40
AM acetylated cytochrome c was added and the change in
absorbance at 550 nm was measured for 1 min at 37 jC with
a Beckman spectrophotometer. Background absorbance for
all groups was determined by the addition of SOD (1000
units/ml).
2.5. Markers for apoptosis
TUNEL (terminal (TdT)-mediated dUTP-biotin nick
end labeling) staining was performed using ApoTag Plus
kit (Intergen Company, Purchase, NY) according to the
manufacturer’s instructions. Caspase-3-like activity was
measured using the synthetic peptide N-acetyl-DEVD-
AMC (BD PharMingen, San Diego, CA). This assay
detects activated caspase-3 and, to a lesser extent, cas-
pase-6, -7, and -8. Although the caspase-3 assay can
detect caspase-8, the difference in sensitivity for the two
caspases in the assay (the assay is 20-fold more sensitive
for caspase-3) argues that a substantial portion of the
signal is caspase-3. Caspase-1 like activity was measured
using the synthetic peptide N-acetyl-YVAD-AMC (BD
PharMingen). Active caspases will cleave the AMC from
the peptide and the free AMC will fluoresce. Standards
of active caspase-3 and caspase-1 were also prepared.
Briefly, 1 ml of assay buffer (20 mM HEPES, 10%
glycerol, 2 mM DTT (2 Al of a 1 M solution) and 14 Al
of peptide/ml of buffer) and 50 Al of sample were added
to a microcentrifuge tube and protected from the light.
Samples were incubated at 37 jC for 60 min (caspase-3)
or 120 min (caspase-1); after which fluorescence was
measured on a spectrofluorometer with an excitation
wavelength of 380 nm and an emission wavelength of
440 nm. Cytosolic cytochrome c was quantified using an
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ELISA kit from R&D Systems (Minneapolis, MN). The
cytochrome c assay is calibrated against a highly purified
natural rat cytochrome c protein isolated from rat heart.
Based upon amino acid analysis, the molecular weight of
this protein is 12.1 kDa and contains less than 5% of the
reduced form of cytochrome c. This immunoassay rec-
ognizes both the oxidized and reduced forms of cyto-
chrome c. Moreover, the cross-reactivity is approximately
7.2% and the limit of detection is 0.5 ng/ml, while the
intra-assay and inter-assay precision is between 1% and
4%. Results were reported as arbitrary fluorescence units
normalized to milligrams of protein.
2.6. Protein concentration
Cytosolic and mitochondrial protein concentrations were
determined using the method developed by Bradford [20].
2.7. Statistical analysis
All experiments were performed successfully at least
three times. Unpaired t tests were used for comparisons
between two groups and analysis of variance with a Tukey
post hoc test was used for multiple comparisons. Analysis of
variance with repeated measure was performed when multi-
ple time points were recorded from the same sample. All
statistics were calculated using a statistical package from
Prism (San Diego, CA). A P value of <0.05 was considered
significant.
3. Results
3.1. Toxic effects of doxorubicin treatment in an H9C2
cultured myocyte cell line
We evaluated the role of oxidant production, mito-
chondrial dysfunction, and apoptosis in doxorubicin tox-
icity using a myocyte cell line as well as isolated heart
mitochondria. Doxorubicin exposure resulted in dose-
dependent toxicity in the H9C2 cardiac myocyte cell line
as determined by both the MTT and calcein AM viability
assay (Fig. 1). The conversion of MTT to a formazan
product by mitochondrial dehydrogenases was used as an
index of mitochondrial viability, and the calcein AM
assay, which depends upon cleavage by cytosolic esterase
activity, was used as an indicator of cellular viability.
There was a significant reduction in mitochondrial func-
tion using nanomolar concentrations of doxorubicin
although loss of viability required micromolar concentra-
tions, indicating that low concentrations of doxorubicin
are sufficient to cause significant mitochondrial dysfunc-
tion, but not a significant loss in cell number (Fig. 1).
Greater reduction in mitochondrial function was seen
with a concentration of 10 AM. This dose reduced
MTT conversion by about 30%, which corresponded to
a significant decline in cell viability, suggesting that this
dose caused not only damage to the mitochondrial
population but also may have induced an increased rate
of apoptosis. We continued to use 10 AM concentration
of doxorubicin in our experiments since similar levels are
seen transiently in plasma following pharmaceutical use
in patients. Time course analysis revealed a reduction in
Fig. 1. Doxorubicin exposure reduces viability of H9C2 cells. H9C2 cells
were exposed to very low (nM) and high concentrations (10 AM) of
doxorubicin. Mitochondrial viability was determined using the MTT
conversion assay and cellular viability was determined by the Calcein AM
assay 20 h after addition of doxorubicin (see Methods). There was an
immediate reduction (nm concentrations) in mitochondrial function
determined by MTT conversion rate. Both the 100 nM, 1 AM, and 10
AM concentrations of doxorubicin are significantly ( P<0.05) different from
control. In contrast, the calcein assay (cellular viability) was not significant
until 10 AM of doxorubiucin. Data were normalized to untreated cells as
100% and shown as meanFS.E. for 8 wells per group versus vehicle-treated
cells. *P<0.05 vs. control.
Fig. 2. Doxorubicin exposure of H9C2 cells results in inhibition of
mitochondrial MTT conversion prior to cell death. H9C2 were exposed to
10 AM doxorubicin and viability was determined after 3, 6, 9, and 20 h.
Mitochondrial function determined by the MTT viability assay was reduced
more rapidly as compared to cellular viability. Data were normalized to
untreated control cells at each time point and shown as meanFS.E. for 4–6
wells per group. *P<0.05 vs. control.
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MTT conversion as early as 3 h in some experiments but
reproducibly was lower 6 h following exposure to 10 AM
doxorubicin (Fig. 2). In contrast, using the calcein AM
assay, the toxic effects of 10 AM doxorubicin were not
seen until 9 h of exposure (Fig. 2). The difference in the
time course of these viability markers indicates that
mitochondrial dysfunction is an early event in doxorubi-
cin toxicity in these cells.
3.2. Evidence for doxorubicin-induced apoptosis in the
H9C2 cell line
H9C2 cells were exposed to low (1 nM) and high
concentrations (10 AM) of doxorubicin for 20 h. Exposure
of H9C2 cells to 10 AM of doxorubicin for 20 h resulted in a
45% increase in TUNEL-positive cells (Fig. 3). This is
notable as there was an overall decrease in total nuclei,
Fig. 3. Doxorubicin exposure increases cell death and TUNEL-positive nuclei in H9C2 cells. Top panels show photomicrographs of doxorubicin-treated H9C2
cells. H9C2 cells were plated at a density of 5000 cells per well in a 16-well slide and were exposed to 10 AM doxorubicin for 20 h. The top two panels are
phase-contrast micrographs taken prior to TUNEL staining and the bottom two panels show the results of the TUNEL stain. Noticed marked swelling of H9C2
cells and an increase in the size of the nuclei occurred. The TUNEL analysis was quantified and bottom figure depicts the percent of total nuclei stained
positive. Shown are meanFS.E. for n=8 wells per group. *P<0.001 vs. control.
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strongly suggesting the involvement of apoptosis in doxor-
ubicin toxicity in these cells. In addition, profound swelling
of myocytes and cell nuclei was observed upon doxorubicin
administration. A further indication of apoptosis, 10 AM
doxorubicin caused an increase in nuclei with chromatin
condensation visualized by propidium iodide staining (data
not shown). With 1 AM doxorubicin, only 5.6% of nuclei
were TUNEL positive (data not shown). There was no effect
of lower concentrations of doxorubicin (1 nM) on TUNEL
staining. These results indicate that the increase in apoptotic
nuclei occurs in a similar dose range as the loss in cell
number, indicating the importance of apoptosis in doxor-
ubicin toxicity in these cells.
3.3. Effects of doxorubicin on isolated rat mitochondria
We used mitochondria isolated from rat hearts, since
using our cell line it would have been very difficult to
isolate sufficient mitochondrial protein for assay analysis.
Further, H9C2 cells are rat heart derived; therefore, the
mitochondria are from a similar source. Doxorubicin expo-
sure (10 AM) resulted in a remarkable increase in superoxide
anion production by isolated rat heart mitochondia (Fig. 4).
The increase in superoxide production was rapid (within 5
min) and peaked at 15 min following treatment. This
increase in superoxide production persisted through 1 h of
exposure. The very modest decline in superoxide production
(15% after 30 min) is not statistically significant (P=0.18)
Fig. 4. Doxorubicin rapidly increased superoxide anion production in
isolated rat heart mitochondria. Mitochondria were isolated from a
Sprague–Dawley rat heart to obtain sufficient amounts of mitochondria
to determine superoxide production. Following the isolation, mitochondria
(0.5 mg/ml) were treated with 10 AM doxorubicin and cytochrome c
reduction was monitored at the different time points. Superoxide production
increased rapidly and was sustained for at least 1 h. Shown are meanFS.E.
for n=4. *P<0.05 vs control.
Fig. 5. Doxorubicin treatment increases cytochrome c efflux from isolated
rat heart mitochondria. Mitochondria were incubated with doxorubicin (10
AM) for 3 h at 37 jC. Mitochondria were pelleted by centrifugation at
7700g for 7 min and cytochrome c concentration in the supernatant was
determined using an ELISA. Shown are meanFS.E. for n=4. *P<0.05 vs.
control.
Fig. 6. Doxorubicin treatment increases caspase-3, but not caspase-1,
activities in H9C2 cells. Cells were treated with 10 AM doxorubicin for 6 h.
Caspase-3 (A) and caspase-1 (B) activities were determined in the cytosolic
fraction as described in Methods. Shown are meanFS.E. for n=7. *P<0.01
vs control.
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and may represent normal variability in the assay. Alter-
natively, superoxide production may be decreasing from the
peak in the doxorubicin-treated mitochondria and be due to
destruction of mitochondria. These data demonstrate the
intensity of the oxidative burst to produce superoxide anions
due to doxorubicin treatment.
3.4. Markers of apoptosis
Doxorubicin treatment of isolated mitochondria showed a
significant increase in cytochrome c efflux into the assay
supernatant (Fig. 5), implicating mitochondrial dysfunction
and activation of permeability transition due to doxorubicin
toxicity. The high background levels of cytochrome c (Fig.
5) could be attributed to (1) significant levels of cytochrome
c being present in the cytosol, (2) leakage (structural dam-
age) during the isolation procedures, and (3) activation of
permeability transition. However, the differences observed
between control and the treatment group indicates a greater
release of cytochrome c due to doxorubicin. Furthermore,
caspase-3, a major ‘‘effector caspase’’, was significantly
elevated in the H9C2 cardiac cell line following doxorubicin
treatment (Fig. 6A). In contrast, caspase-1 activity (Fig. 6B),
a mitochondrial independent pathway, was not affected by
doxorubicin treatment. These results suggest that the mito-
chondrial-mediated pathway is important in inducing apop-
tosis under these conditions (see Discussion).
4. Discussion
Doxorubicin (adriamycin) is an anthracycline antibiotic
that is used as a potent anticancer agent; however, it is
exceptionally cytotoxic to the heart. Toxicity is believed to
occur by doxorubicin-induced mitochondrial dysfunction
and subsequent oxidant production. [21,22]. The heart is
especially prone to oxidative damage due to high levels of
enzymes with reductase and dehydrogenase properties, such
as NADPH dehydrogenase and endothelial nitric oxide
synthase (NOS), which play major roles in transferring
electrons to generate oxidant species [5,6]. In our study,
doxorubicin treatment of cultured myocytes induced apop-
tosis as determined by TUNEL staining of nuclei and
caspase-3 activation. Interestingly, a rapid decline in mito-
chondrial reduction potential precedes cell death by approx-
imately 6 h, implicating mitochondrial dysfunction as an
early event in doxorubicin-induced cardiotoxicity. In sup-
port of this hypothesis, we also found that doxorubicin
results in a very rapid (within 5 min) increase in superoxide
production in isolated rat heart mitochondria and this is
followed by release of the pro-apoptotic protein cytochrome
c. Our experiments differ from the literature in that we
examined rapid effects on mitochondrial function that were
shown to precede myocyte death/apoptosis. Our results not
only indicate that doxorubicin treatment can lead to oxida-
tive stress, mitochondrial dysfunction, and apoptosis, but
describe a temporal relationship between these variables.
Thus, very low (nM) concentrations of doxorubicin caused a
rapid decline in mitochondrial reduction potential, which
precedes cell death by approximately 6 h, implicating
mitochondrial dysfunction as an early event in doxorubi-
cin-induced myocyte apoptosis.
We showed that mitochondria isolated from rat heart
treated with pharmacological levels of doxorubicin produce
a f4-fold greater amount of O2
 compared to nontreated
mitochondria and superoxide production persisted through 1
h of exposure. The rapid and sustained oxidant production
could cause oxidative stress. Indeed, Luo et al. [23] showed
that reactive aldehydes (malondialdehyde, hexanal and 4-
hydroxy-non-2-enal) in rat plasma and heart tissues
increased significantly following doxorubicin treatment.
Importantly, changes occurred early, peaked around 2 h
after doxorubicin administration, and the levels declined or
returned to baseline value within 8–24 h [23]. Oxidative
stress after doxorubicin treatment could therefore be directly
responsible for the development of functional abnormalities
also documented by echocardiography abnormalities in this
study [23].
Which oxidant is responsible for oxidative stress contin-
ues to be a heavily debated topic. NO can rapidly scavenge
superoxide produced in the mitochondria, because NO out-
competes the superoxide scavenging enzyme superoxide
dismutase (SOD) for O2
. Therefore, O2
 produced during
doxorubicin toxicity and scavenged by NO may produce the
strong oxidant peroxynitrite (ONOO). There are studies
that support superoxide anion as the major cause for
oxidative stress, whereas others suggest that hydrogen per-
oxides and peroxynitrite are more relevant oxidants inducing
oxidative stress. In support of a primary role of superoxide
production in doxorubicin toxicity, the overexpression of
manganese superoxide dismutase has been shown to be
cardioprotective in mice five days after doxorubicin treat-
ment [14]. However, other studies suggest that doxorubicin-
induced hydrogen peroxide formation is responsible for the
toxicity [13]. Hydrogen peroxide production is also directly
related to the production of the superoxide anion. Further-
more, hydrogen peroxide production could function as a
gene regulator and increase transcription of eNOS [5,6],
thereby increasing NO. Alternatively, studies have shown
that doxorubicin interacts with eNOS (reductase enzyme
moiety) and produce additional superoxide radicals [4–
6,24]. We recently demonstrated that there is an increase
in plasma iron levels after doxorubicin treatment, suggesting
that hydroxyl radical formation is also a likely candidate for
free radical damage [25]. Although there is debate over
which specific radical is responsible for oxidative damage, it
is likely a combination of all these oxidants and their
respective reactions are involved in the pathophysiological
events leading to cardiomyopathies.
Since oxidants are a major factor in reducing cellular
ATP, glutathione, and other reducing equivalents, such as
NADPH, they increase the susceptibility of the mitochon-
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dria to undergo permeability transition. We show that
mitochondrial dysfunction was prevalent in the early stages
of doxorubicin treatment and may have been directly
responsible for the apoptotic cell death observed. Moreover,
we believe that a threshold of mitochondrial destruction
needs to be reached before a cell will die. Very low levels of
doxorubicin caused a reduction in mitochondrial function,
but not cell death.
Additional in vitro studies will determine if the mecha-
nism of doxorubicin action on apoptosis is the same using
various doses for longer time periods in the H9C2 cells.
These studies would use lower concentrations (e.g. 0.1–2
AM) to study the effects on cardiomyocyte apoptosis.
However, long-term use of doxorubicin in cell culture and
specifically mitochondria may be very difficult and different
from its use in vivo. Chronic, low concentration studies in
isolated mitochondria are not feasible due to difficulties in
maintaining mitochondrial viability for longer than 2 h. In
addition, in vivo and in vitro studies are needed using a low
chronic dosage since other death pathways of apoptosis,
such as the receptor-mediated pathway, may also be very
relevant. In vivo studies use an acute dose of 20 mg/kg of
doxorubicin in animals or lower chronic doses, which are all
likely to increase plasma levels greater than 10 AM tran-
siently and may only represent clinical conditions for a short
period of time. However, some of the effects described in
our study are rapid, and therefore could occur in patients
since high concentrations could be reached transiently.
Others have also shown that doxorubicin can cause
apoptosis in the rat heart [26]. In addition, apoptosis occurs
in cell culture models and isolated myocytes exposed to
doxorubicin [6,27,28]. The production of oxidant radicals,
specifically hydrogen peroxides [6], is able to increase
cytochrome c release and induce apoptosis. We found
significant release of cytochrome c levels in myocytes
treated with doxorubicin. Although apoptosis can occur
via cytochrome c-independent mechanisms, it is well estab-
lished that in most cell types, once cytochrome c is released
it interacts with Apaf-1 and procaspase-9, leading to the
generation of active caspase-9, which is capable of proteo-
lytically activating caspase-3. Active caspase-3 can then
initiate the apoptotic degradation phase [16]. We observed
significant increases in caspase-3 activity, but not in cas-
pase-1 activity, which is a well-known cytochrome c-inde-
pendent caspase.
However, there are several other pathways that can
activate caspase-3. For example, caspase-8 is able to acti-
vate caspase-3, and therefore this receptor-mediated path-
way may also be intricately involved in the cell death
observed. However, under these in vitro experimental con-
ditions we believe that the activity of caspase-3 is mainly
attributed to the mitochondrial pathway. We expect that
investigating chronic doxorubicin toxicity in animals may
give more insight on activation of receptor mediated path-
ways, since doxorubicin has also been shown to activate
cytokines [29] and could have effected caspase-1 and
caspase-8, which are thought to be primarily activated by
receptor-mediated pathways. Since systemic alterations
could occur after doxorubicin treatment, responses of recep-
tor-mediated pathways need more investigation. Further-
more, caspase-12, an endoplasmic reticulum-mediated
pathway, has received attention since it can be activated
by endoplasmic reticulum-mediated stress and releases
calcium, which activates caspase-12. Once caspase activa-
tion occurs, it may be responsible for cytoskeletal alterations
that can result in cell shrinkage and negatively affect tension
development [30], two events important for the develop-
ment of chronic cardiomyopathies.
Therefore, other research efforts will further explore the
use of specific antioxidants and caspase inhibitors to prevent
apoptosis. Ebselen and lipoic acid could provide a sufficient
water and lipid soluble antioxidant buffer to reduce oxida-
tive stress and apoptosis. In addition, the prodomain of
proximal caspases contains a caspase recruitment domain
(CARD) for the activation or inhibition of caspases. For
example, ARC (apoptosis repressor with a CARD) interacts
with caspase-2 and -8 and functions as an inhibitor [31].
Alternatively, ARC has also been shown to block mitochon-
drial cytochrome c release and prevents caspase-3 activa-
tion, possibly by binding to voltage dependent anion
channels in the mitochondria [32,33], presenting another
avenue to inhibit caspase activation. In addition, we will
attempt to use longer periods of doxorubicin treatment using
lower concentrations to reflect the chronic use of doxorubi-
cin by patients with lymphomas. These efforts to prevent
mitochondrial dysfunction and release of cytochrome c from
the mitochondria and/or inhibit caspase-3 activation may
prove successful in preventing some of the cardiotoxic
effects of doxorubicin.
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